Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Larson on Immunotherapy for Colorectal Cancer

September 26th 2017

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Dr. Yoon on Immunotherapy in Gastric Cancer

September 25th 2017

Harry H. Yoon, MD, associate professor of oncology, Mayo Clinic, discusses the benefits demonstrated with nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with gastric cancer.

FDA Approves Nivolumab for Hepatocellular Carcinoma

September 23rd 2017

The FDA has granted an accelerated approval to nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib.

Dr. Saab on Immunotherapy in MSI-H GI Malignancies

September 23rd 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.

FDA Approves Pembrolizumab for PD-L1+ Gastric Cancer

September 22nd 2017

The FDA has approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.

Expert Reflects on Recent Trial Results in CRC and Small Bowel Cancer

September 21st 2017

Heinz-Josef Lenz, MD, discusses his study of molecular variations between small bowel adenocarcinomas, right-sided colon cancers, and gastroesophageal cancers.

Dr. Janjigian Discusses MSI Testing in Gastric Cancer

September 19th 2017

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.

Study Shows DAAs Are Not Associated With Increased HCC Recurrence Risk

September 18th 2017

Direct acting antivirals are a novel and completely oral hepatitis C therapy that is associated with a high response rate in hepatocellular carcinoma (HCC).

BLU-554 Associated With Improved Response in HCC

September 17th 2017

BLU-554 induced an overall response rate of 16% in patients with FGF19-positive hepatocellular carcinoma.

Dr. Welling on CheckMate-040 Trial of Nivolumab in HCC

September 17th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the purpose of the CheckMate-040 trial, which explored nivolumab (Opdivo) in patients with hepatocellular carcinoma. (HCC).

Dr. Montal on Molecular Predictors of Recurrence With Adjuvant Sorafenib in HCC

September 17th 2017

Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses biomarker findings of the phase III STORM trial, which explored adjuvant treatment with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

Lenvatinib Continues to Show Noninferiority to Sorafenib in Liver Cancer

September 17th 2017

First-line therapy with lenvatinib continued to be noninferior in overall survival and achieve significant improvements in progression-free survival, time to progression, and objective response rate compared with sorafenib for patients with unresectable hepatocellular carcinoma.

STORM Study Fails to Find Predictive Biomarkers for Sorafenib in HCC

September 16th 2017

Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival for patients with hepatocellular carcinoma treated with adjuvant sorafenib; however, a predictive biomarker for recurrence was not uncovered.

Precision Screening May Improve Surveillance in HCC

September 16th 2017

Precision screening for hepatocellular carcinoma (HCC) could improve on current screening techniques through its risk-stratifying approach.

Dr. Finn on Significance of Phase III Findings of Lenvatinib in HCC

September 16th 2017

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

Dr. Welling on Incorporating Immunotherapy Into HCC Paradigm

September 16th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agents will eventually fit into the paradigm of hepatocellular carcinoma. (HCC).

Mounting Excitement in HCC Examined at ILCA Meeting

September 16th 2017

Theodore H. Welling, MD, shares insight on the top presentations at the ILCA meeting, and how he believes the future will look for the treatment of HCC.

Dr. Montal on Systemic Therapy Advancements in HCC

September 16th 2017

Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses advancements regarding systemic therapies in the field of hepatocellular carcinoma (HCC).

Dr. Finn on Current and Emerging Agents in the Field of HCC

September 16th 2017

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).

Finn Highlights Practice-Changing Studies in Liver Cancer

September 16th 2017

The 11th International Liver Cancer Association Annual Conference, taking place September 15 to 17 in Seoul, South Korea, is showcasing multidisciplinary findings across the field of hepatocellular carcinoma.